drugset / Trial / NCT01009775
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage IV melanoma.
Timeline
- Start
- 2009-11
- Primary completion
- 2011-03
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | SEPANTRONIUM | Small molecule | — | Intravenous |